Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering
Provides Additional Financial Flexibility in Exchange for New Warrants with a $6.385 Exercise Price Company to hold a business update conference call the week of October 3rd CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it has entered into amended agreements to extend the … [Read more…]
